Advertisement

Tumor Necrosis Factor Inhibitors May Have Limited Efficacy for Complex Perianal Fistulas Without Luminal Crohn’s Disease

  • Jeffrey D. McCurdyEmail author
  • Simon Parlow
  • Yvonne Dawkins
  • K. Samji
  • Glara Gaeun Rhee
  • Lilianna Oliveira
  • Blair Macdonald
  • Elham Sabri
  • Sanjay Murthy
Original Article
  • 54 Downloads

Abstract

Background

Complex perianal fistulas occurring in the absence of luminal inflammation (isolated perianal disease, IPD) may represent a specific phenotype of Crohn’s disease (CD).

Aim

We assessed the effectiveness of tumor necrosis factor (TNF)-antagonists in patients with IPD compared to those with perianal CD (PCD) with luminal inflammation.

Methods

Patients were identified through our institutional radiology database and were classified as PCD or IPD based on the presence or absence of luminal inflammation by ileocolonoscopy and abdominal enterography. Consecutive adults (> 17 years) with recurrent IPD who were treated with TNF antagonists were matched by age and gender to patients with complex PCD (1:2 ratio). Fistula remission was defined as an absence of fistula drainage. Surgery-free survival was assessed by Cox proportional hazard models.

Results

Twenty-two patients with IPD treated with a TNF antagonist were compared with 44 matched patients with PCD. A similar proportion of patients with IPD and PCD were treated with concomitant immunomodulators (55% vs. 66%) and underwent examinations under anesthesia prior to therapy (36% vs. 46%). Fistula remission at 3, 6, and 12 months was lower for the IPD cohort: 9.5% versus 34%; 19% versus 39%; and 19% versus 43%. Surgical intervention after initiating anti-TNF therapy was more common for patients with IPD (HR 3.99: 95% CI, 1.62–9.83; p = 0.0026).

Conclusions

Fewer patients with IPD achieved fistula remission, and more required surgical intervention after anti-TNF therapy, suggesting that TNF antagonists may not be as effective in these patients.

Keywords

Fistula-in-ano Cryptoglandular fistulas Perianal fistulas Tumor necrosis factor Crohn’s disease 

Notes

Author’s contribution

SP acquired and analyzed the data. YD and GR acquired the data. BM contributed to MRI analysis and critical review of the manuscript. LO and SM critically reviewed the manuscript. ES analyzed the data. JDM contributed to the study concept design, data analysis, and drafting of the manuscript. All authors have approved the final version of the manuscript.

Compliance with Ethical Standards

Conflict of interest

JD and SM: Honoraria from Takeda, Jansen, Abbvie, and Ferring.

Supplementary material

10620_2019_5905_MOESM1_ESM.docx (51 kb)
Supplementary material 1 (DOCX 50 kb)

References

  1. 1.
    Kasparek MS, Glatzle J, Temeltcheva T, et al. Long-term quality of life in patients with Crohn’s disease and perianal fistulas: influence of fecal diversion. Dis Colon Rectum. 2007;50:2067–2074.CrossRefGoogle Scholar
  2. 2.
    Ng SC, Plamondon S, Gupta A, et al. Prospective assessment of the effect on quality of life of anti-tumour necrosis factor therapy for perineal Crohn’s fistulas. Aliment Pharmacol Ther. 2009;30:757–766.CrossRefGoogle Scholar
  3. 3.
    Chaparro M, Zanotti C, Burgueno P, et al. Health care costs of complex perianal fistula in Crohn’s disease. Dig Dis Sci. 2013;58:3400–3406.  https://doi.org/10.1007/s10620-013-2830-7.CrossRefPubMedGoogle Scholar
  4. 4.
    Schwartz DA, Loftus EVJ, Tremaine WJ, et al. The natural history of fistulizing Crohn’s disease in Olmsted County, Minnesota. Gastroenterology. 2002;122:875–880.CrossRefGoogle Scholar
  5. 5.
    Hellers G, Bergstrand O, Ewerth S, et al. Occurrence and outcome after primary treatment of anal fistulae in Crohn’s disease. Gut. 1980;21:525–527.CrossRefGoogle Scholar
  6. 6.
    Vogel JD, Johnson EK, Morris AM, et al. Clinical practice guideline for the management of anorectal abscess, fistula-in-ano, and rectovaginal fistula. Dis Colon Rectum. 2016;59:1117–1133.CrossRefGoogle Scholar
  7. 7.
    Eglinton TW, Barclay ML, Gearry RB, et al. The spectrum of perianal Crohn’s disease in a population-based cohort. Dis Colon Rectum. 2012;55:773–777.CrossRefGoogle Scholar
  8. 8.
    Gecse KB, Bemelman W, Kamm MA, et al. A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn’s disease. Gut. 2014;63:1381–1392.CrossRefGoogle Scholar
  9. 9.
    Garcia-Aguilar J, Belmonte C, Wong WD, et al. Anal fistula surgery. Factors associated with recurrence and incontinence. Dis Colon Rectum. 1996;39:723–729.CrossRefGoogle Scholar
  10. 10.
    Mahmoud NN, Halwani Y, de Montbrun S, et al. Current management of perianal Crohn’s disease. Curr Probl Surg. 2017;54:262–298.CrossRefGoogle Scholar
  11. 11.
    Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132:52–65.CrossRefGoogle Scholar
  12. 12.
    Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med. 2004;350:876–885.CrossRefGoogle Scholar
  13. 13.
    Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med. 1999;340:1398–1405.CrossRefGoogle Scholar
  14. 14.
    Sandborn WJ, Fazio VW, Feagan BG, et al. AGA technical review on perianal Crohn’s disease. Gastroenterology. 2003;125:1508–1530.CrossRefGoogle Scholar
  15. 15.
    Ford AC, Sandborn WJ, Khan KJ, et al. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106:644–59.  https://doi.org/10.1038/ajg.2011.73.Google Scholar
  16. 16.
    Shenoy-Bhangle A, Nimkin K, Goldner D, et al. MRI predictors of treatment response for perianal fistulizing Crohn disease in children and young adults. Pediatr Radiol. 2014;44:23–29.CrossRefGoogle Scholar
  17. 17.
    Brochard C, Landemaine A, L’Heritier AM, et al. Anal fistulas in severe perineal Crohn’s disease: Mri assessment in the determination of long-term healing rates. Inflamm Bowel Dis. 2018;24:1612–1618.CrossRefGoogle Scholar
  18. 18.
    Adler SN, Yoav M, Eitan S, et al. Does capsule endoscopy have an added value in patients with perianal disease and a negative work up for Crohn’s disease? World J Gastrointest Endosc. 2012;4:185–188.CrossRefGoogle Scholar
  19. 19.
    Stevens TW, D’Haens GR, Duijvestein M, et al. Diagnostic accuracy of faecal calprotectin in patients with active perianal fistulas. United European Gastroenterol J. 2019;7:496–506.CrossRefGoogle Scholar
  20. 20.
    Oliveira IS, Kilcoyne A, Price MC, et al. MRI features of perianal fistulas: is there a difference between Crohn’s and non-Crohn’s patients? Abdom Radiol (NY). 2017;42:1162–1168.CrossRefGoogle Scholar
  21. 21.
    Zbar AP, Horesh N, Bucholtz V, et al. Are there specific endosonographic features in Crohn’s patients with perianal fistulae? Journal of Crohn’s and Colitis. 2013;7:490–496.CrossRefGoogle Scholar
  22. 22.
    Blom J, Nystrom PO, Gunnarsson U, et al. Endoanal ultrasonography may distinguish Crohn“s anal fistulae from cryptoglandular fistulae in patients with Crohn”s disease: a cross-sectional study. Tech Coloproctol. 2011;15:327–330.CrossRefGoogle Scholar
  23. 23.
    van Onkelen RS, Gosselink MP, van Meurs M, et al. Pro-inflammatory cytokines in cryptoglandular anal fistulas. Tech Coloproctol. 2016;20:619–625.CrossRefGoogle Scholar
  24. 24.
    Kiehne K, Fincke A, Brunke G, et al. Antimicrobial peptides in chronic anal fistula epithelium. Scand J Gastroenterol. 2007;42:1063–1069.CrossRefGoogle Scholar
  25. 25.
    Owen G, Keshava A, Stewart P, et al. Plugs unplugged. Anal fistula plug: the Concord experience. ANZ J Surg. 2010;80:341–343.CrossRefGoogle Scholar
  26. 26.
    Schwandner O, Stadler F, Dietl O, et al. Initial experience on efficacy in closure of cryptoglandular and Crohn’s transsphincteric fistulas by the use of the anal fistula plug. Int J Colorectal Dis. 2008;23:319–324.CrossRefGoogle Scholar
  27. 27.
    Gingold DS, Murrell ZA, Fleshner PR. A prospective evaluation of the ligation of the intersphincteric tract procedure for complex anal fistula in patients with Crohn’s disease. Ann Surg. 2014;260:1057–1061.CrossRefGoogle Scholar
  28. 28.
    Soltani A, Kaiser AM. Endorectal advancement flap for cryptoglandular or Crohn’s fistula-in-ano. Dis Colon Rectum. 2010;53:486–495.CrossRefGoogle Scholar
  29. 29.
    Mizrahi N, Wexner SD, Zmora O, et al. Endorectal advancement flap: are there predictors of failure? Dis Colon Rectum. 2002;45:1616–1621.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Division of Gastroenterology and HepatologyThe Ottawa HospitalOttawaCanada
  2. 2.Department of Medical ImagingThe Ottawa HospitalOttawaCanada
  3. 3.The Ottawa Hospital Research InstituteThe Ottawa HospitalOttawaCanada

Personalised recommendations